Table 6. Univariate and multivariate Cox-proportional hazard regression analyses predicting PFS and OS in DLBCL patients.
| Variables | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Univariate P value | Multivariate HR (95% CI) | P value | Univariate P value | Multivariate HR (95% CI) | P value | |
| Age (> 60) | 0.032 | 4.04 (1.17–14.01) | 0.027 | 0.031 | 0.44 (0.12–1.65) | 0.224 |
| B symptom | 0.023 | 1.40 (0.54–3.64) | 0.487 | 0.026 | 1.39 (0.55–3.51) | 0.493 |
| ECOG PS (≥ 2) | 0.009 | 0.23 (0.04–1.27) | 0.095 | 0.026 | 0.55 (0.15–1.97) | 0.356 |
| Stage (≥ 3) | 0.123 | 0.170 | ||||
| LDH (> normal) | 0.080 | 0.085 | ||||
| IPI | 0.046 | 2.80 (0.64–12.22) | 0.171 | 0.058 | ||
| NCCN-IPI | 0.004 | 0.25 (0.05–1.23) | 0.088 | 0.003 | 1.91 (0.73–5.03) | 0.036 |
| Combined PET BMI and IgH BMI | 0.007 | 4.83 (1.17–19.97) | 0.030 | 0.035 | 2.30 (0.63–8.49) | 0.210 |
Univariate analysis and multivariate Cox-proportional hazard regression analysis was conducted using the Breslow method. Multivariate analysis was performed using the covariates, which showed a P value of less than 0.05 in the univariate analysis.
PFS = progression-free survival, OS = overall survival, DLBCL = diffuse large B-cell lymphoma, CI = confidence interval, HR = hazard ratio, ECOG PS = Eastern Cooperative Oncology Group performance score, LDH = lactate dehydrogenase, IPI = International Prognostic Index, NCCN-IPI = National Comprehensive Cancer Network-IPI, PET BMI = positron emission tomography-computed tomography bone marrow involvement, IgH BMI = immunoglobulin heavy chain rearrangement bone marrow involvement.